Retrospective Study
Copyright ©The Author(s) 2016.
World J Hepatol. Dec 8, 2016; 8(34): 1511-1520
Published online Dec 8, 2016. doi: 10.4254/wjh.v8.i34.1511
Table 1 Baseline clinical characteristics of patients with chronic hepatitis B according to treatment response after 96-wk nucleos(t)ide analogues therapy
ParametersOverallVR (+)VR (-)P valueSC (+)SC (-)P value
n (%)7643 (56.6)33 (43.4)-15 (19.7)61 (80.3)-
Gender, female/male20/5615/285/280.0535/1015/460.491
Age, yr32.63 ± 9.6932.3 ± 9.8333.06 ± 9.630.73831.87 ± 11.632.82 ± 9.260.735
HBsAg, lg IU/mL3.95 ± 0.833.96 ± 0.683.94 ± 1.000.8813.93 ± 0.603.96 ± 0.880.385
HBeAg, lg PEIU/mL2.24 ± 1.312.18 ± 1.382.32 ± 1.220.6792.36 ± 1.412.21 ± 1.290.527
anti-HBc, lg IU/mL4.77 ± 0.464.82 ± 0.434.71 ± 0.500.3114.85 ± 0.444.75 ± 0.470.464
ALT, U/L213.73 ± 157.17247.95 ± 150.58169.13 ± 156.560.029216.49 ± 153.18213.05 ± 159.380.94
ALT strata, ≥/< 5ULN31/4525/186/27< 0.0019/622/390.091
HBV DNA, lg copies/mL8.16 ± 1.348.06 ± 1.458.3 ± 1.190.6088.55 ± 0.918.07 ± 1.410.324
Genotype, C/non-C53/2331/1222/110.6110/543/180.773
Table 2 Baseline and on-treatment parameters associated with 96-wk virological response and hepatitis B e antigen seroconversion in chronic hepatitis B patients received nucleos(t)ide analogues therapy
FactorsVR
SC
Univariate
Multivariate
Univariate
Multivariate
OR (95%CI)P valueOR (95%CI)P valueOR (95%CI)P valueOR (95%CI)P value
Baseline
Age0.99 (0.95-1.04)0.734--0.99 (0.93-1.05)0.731--
Sex, female/male3 (0.96-9.38)0.0593.76 (1.09-13.01)0.0371.53 (0.45-5.20)0.493--
HBsAg (lg IU/mL)1.04 (0.60-1.81)0.879--0.96 (0.49-1.88)0.904--
HBeAg (lg PEIU/mL)0.92 (0.65-1.31)0.633--1.1 (0.70-1.72)0.682--
Anti-HBc (lg IU/mL)1.68 (0.62-4.59)0.308--1.6 (0.46-5.50)0.459--
HBV DNA (lg copies/mL)0.87 (0.62-1.24)0.451--1.38 (0.82-2.31)0.221--
ALT (U/L)1.004 (1.000-1.007)0.038--1 (0.99-1.01)0.939--
ALT strata, ≥/< 5ULN6.25 (2.14-18.26)< 0.0017.09 (2.32-21.67)< 0.0012.66 (0.84-8.46)0.098--
Genotype, C/non-C1.29 (0.48-3.46)0.61--0.84 (0.25-2.80)0.773--
Week 12
HBsAg (lg IU/mL)0.83 (0.45-1.53)0.551--0.95 (0.47-1.92)0.882--
HBsAg decline (lg IU/mL)1.43 (0.72-2.84)0.301--1.04 (0.46-2.35)0.919--
HBeAg (lg PEIU/mL)0.5 (0.33-0.76)0.0010.62 (0.40-0.95)0.030.5 (0.30-0.85)0.011--
HBeAg decline (lg PEIU/mL)3.04 (1.55-5.98)0.0012.58 (1.25-5.33)0.012.47 (1.46-4.16)< 0.0012.47 (1.46-4.16)0.001
Anti-HBc (lg IU/mL)1.14 (0.49-2.64)0.764--2.56 (0.83-7.93)0.102--
Anti-HBc decline (lg IU/mL)1.43 (0.45-4.59)0.546--0.3 (0.06-1.51)0.145--
ALT (U/L)0.99 (0.98-1.01)0.221--1 (0.98-1.02)0.876--
ALT decline (U/L)1.004 (1.00-1.01)0.03--1 (0.99-1.01)0.918--
HBV DNA (lg copies/mL)0.57 (0.36-0.90)0.016--0.72 (0.42-1.25)0.249--
HBV DNA decline (lg copies/mL)1.36 (0.90-2.03)0.141--2.11 (1.16-3.84)0.015--
Week 24
HBsAg (lg IU/mL)0.61 (0.31-1.21)0.155--0.84 (0.48-1.46)0.535--
HBsAg decline (lg IU/mL)1.79 (0.94-3.42)0.076--1.21 (0.62-2.37)0.571--
HBeAg (lg PEIU/mL)0.39 (0.24-0.64)< 0.0010.45 (0.27-0.77)0.0030.28 (0.14-0.58)< 0.0010.37 (0.17-0.81)0.013
HBeAg decline (lg PEIU/mL)2.37 (1.41-3.99)0.0012.03 (1.10-3.74)0.0242.8 (1.64-4.78)< 0.0012.02 (1.17-3.49)0.012
Anti-HBc (lg IU/mL)0.73 (0.33-1.63)0.448--1.29 (0.48-3.45)0.608--
Anti-HBc decline (lg IU/mL)3.11 (0.99-3.79)0.053--1.11 (0.31-3.99)0.874--
ALT (U/L)0.99 (0.98-1.01)0.477--0.99 (0.96-1.02)0.516--
ALT decline (U/L)1.004 (1.00-1.01)0.031--1 (0.99-1.01)0.822--
HBV DNA (lg copies/mL)0.55 (0.37-0.80)0.002--0.45 (0.23-0.86)0.016--
HBV DNA decline (lg copies/mL)1.39 (1.02-1.88)0.035--2.39 (1.39-4.11)0.002--
Table 3 Predictive value of hepatitis B e antigen titer as well as its declined value at week 12 and 24 for virological response after 96-wk nucleos(t)ide analogues therapy
FactorsROC
Sensitivity (95%CI)Specificity (95%CI)PPV (95%CI)NPV (95%CI)
AUROC (95%CI)P value
Week 12
HBeAg < 0.8 lg PEIU/mL0.733 (0.617-0.849)0.0010.63 (0.48-0.78)0.81 (0.67-0.96)0.82 (0.68-0.96)0.62 (0.47-0.77)
HBeAg decline > 0.84 lg PEIU/mL0.709 (0.590-0.827)0.0020.65 (0.50-0.80)0.75 (0.59-0.91)0.78 (0.64-0.92)0.62 (0.46-0.78)
Combined the above0.812 (0.687-0.936)< 0.0010.71 (0.54-0.89)0.91 (0.78-1.00)0.91 (0.78-1.00)0.71 (0.54-0.89)
Week 24
HBeAg < 1.3 lg PEIU/mL0.788 (0.683-0.892)< 0.0010.88 (0.78-0.98)0.64 (0.46-0.81)0.76 (0.63-0.88)0.81 (0.65-0.97)
HBeAg decline > 1.6 lg PEIU/mL0.736 (0.620-0.851)< 0.0010.55 (0.39-0.70)0.94 (0.85-1.00)0.92 (0.81-1.00)0.62 (0.48-0.76)
Combined the above0.923 (0.838-1.000)< 0.0010.85 (0.70-0.99)110.83 (0.66-0.99)
Table 4 Predictive value of hepatitis B e antigen titer as well as its declined value at week 12 and 24 for hepatitis B e antigen seroconversion after 96-wk nucleos(t)ide analogues therapy
FactorsROC
Sensitivity (95%CI)Specificity (95%CI)PPV (95%CI)NPV (95%CI)
AUROC (95%CI)P value
Week 12
HBeAg decline > 1.8 lg PEIU/mL0.767 (0.623-0.911)0.0010.6 (0.32-0.88)0.87 (0.78-0.96)0.53 (0.26-0.79)0.9 (0.82-0.98)
Week 24
HBeAg < -0.5 lg PEIU/mL0.828 (0.712-0.944)< 0.0010.67 (0.40-0.94)0.92 (0.84-0.99)0.67 (0.40-0.94)0.92 (0.84-0.99)
HBeAg decline > 2.2 lg PEIU/mL0.814 (0.676-0.953)< 0.0010.73 (0.48-0.99)0.9 (0.82-0.98)0.65 (0.39-0.90)0.93 (0.86-1.00)
Combined the above0.928 (0.791-1.000)< 0.0010.88 (0.58-1.00)0.98 (0.94-1.00)0.88 (0.58-1.00)0.98 (0.94-1.00)